26 studies found for:    WAGR
Show Display Options
RSS Create an RSS feed from your search for:
WAGR
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
Conditions: WAGR Syndrome;   Wilm's Tumor;   Aniridia;   Urogenital Abnormalities;   Mental Retardation
Intervention:
2 Completed
Has Results
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML)
Intervention: Drug: WT1 Peptide Vaccine
3 Completed
Has Results
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Conditions: Leukemia, Acute Myelogenous (AML);   Leukemia, Acute Lymphocytic (ALL);   Leukemia, Chronic Myelogenous (CML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin's Lymphoma (NHL)
Interventions: Drug: WT1 Peptide-Pulsed Dendritic Cells;   Drug: Donor Lymphocytes;   Drug: IL-4;   Drug: KLH;   Drug: WT1 Peptides;   Drug: Endotoxin;   Drug: Diphenhydramine;   Drug: Acetaminophen
4 Recruiting Rare Disease Patient Registry: Coordination of Rare Diseases at Sanford
Conditions: Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome
Intervention:
5 Completed
Has Results
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
Conditions: Myelodysplastic Syndrome (MDS);   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML)
Interventions: Biological: WT1:126-134;   Biological: PR1:169-177 Peptide;   Drug: GM-CSF (Sargramostim);   Biological: Montanide adjuvant
6 Active, not recruiting Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
Condition: Malignant Pleural Mesothelioma
Interventions: Biological: WT-1-vaccine Montanide + GM-CSF;   Biological: Montanide adjuvant + GM-CSF
7 Completed Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome (MDS)
Intervention: Drug: WT1 and PR1 Peptide Vaccine
8 Recruiting Study of Gene Modified WT1 (Wilms' Tumor 1)TCR Therapy in MDS and AML Patients
Conditions: Myelodysplastic Syndromes (MDS);   Acute Myeloid Leukaemia (AML)
Intervention: Genetic: Gene-modified WT1 TCR-transduced T cells intravenous infusion
9 Completed WT1 for the Detection of Minimal Residual Disease
Conditions: Leukemia;   Cancer
Intervention: Procedure: WT 1 Testing
10 Recruiting A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Glioblastoma Multiforme;   Melanoma;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Sarcoma;   Renal Cell Carcinoma
Intervention: Drug: DSP-7888 Dosing Emulsion
11 Unknown  Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Conditions: Acute Myelocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: decitabine
12 Recruiting WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Biological: WT1 Analog Peptide Vaccine;   Biological: Sargramostim (GM-CSF);   Drug: lenalidomide
13 Recruiting Autologous Dendritic Cell Vaccination in Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention: Biological: dendritic cell vaccination plus chemotherapy
14 Recruiting Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients
Condition: Glioblastoma Multiforme of Brain
Intervention: Biological: Dendritic cell vaccine plus temozolomide chemotherapy
15 Recruiting Study of Ataluren in Patients With Aniridia
Condition: Aniridia
Interventions: Drug: Ataluren;   Drug: Placebo
16 Recruiting Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects
Conditions: Full Aniridia;   Partial Aniridia
Intervention: Device: Artificial Iris (CustomFlex)
17 Completed Positive Angle Kappa
Condition: Aniridia
Intervention:
18 Completed Study of the Pathophysiological Mechanisms Involved in Bleeding Events
Condition: Oculocerebrorenal Syndrome
Intervention: Other: Blood sample
19 Active, not recruiting Morcher Artificial Iris Devices to Treat Light and Glare Sensitivity in Partial or Complete Aniridia
Condition: Aniridia
Intervention: Device: Surgery
20 Recruiting Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies
Conditions: Wilms' Tumor;   Aniridia
Interventions: Behavioral: Questionnaire;   Other: Blood specimen

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Indicates status has not been verified in more than two years